Active, Not Recruiting

Trial ID IM032-041 | NCT05730725

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Sorry, this study is no longer accepting new participants, but is still ongoing.

You may click the “Check Your Eligibility” button and answer a few questions about your health to find out if you might be a match to another study.

Check Your Eligibility

Summary

The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.

Diagnosis of plaque psoriasis (PsO) for ≥ 6 months
Body mass index 18 to 40 kg/m^2 and total body weight > 50 kg (110 lbs)
Deemed by Investigator to be eligible for phototherapy or systemic therapy
Psoriatic plaques must cover ≥ 10% of body surface area at baseline
Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician Global Assessment (sPGA) ≥ 3 at baseline

Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic)
Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with PsO for which a participant requires current systemic immunosuppressant medical treatment
Any significant acute or chronic medical illness Other protocol-defined inclusion/exclusion criteria apply

Additional Information *

Study Arms

Experimental: BMS-986322 Dose 1

ASSIGNED INTERVENTION

Study Arms

Experimental: BMS-986322 Dose 2

ASSIGNED INTERVENTION

Study Arms

Experimental: BMS-986322 Dose 3

ASSIGNED INTERVENTION

Study Arms

Placebo Comparator: Placebo

ASSIGNED INTERVENTION